Image

Melanoma Research

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
06/05/2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Data for darovasertib in combination with crizotinib presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
06/05/2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Webinar: Post-ASCO Melanoma Research Update”
05/21/2026

Webinar: Post-ASCO Melanoma Research Update

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
04/19/2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
04/10/2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Advocates Renew Call for RP1 Approval”
03/26/2026

Advocates Renew Call for RP1 Approval

As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
02/19/2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Responds to Patient Advocacy on RP1 + Nivolumab”
02/05/2026

FDA Responds to Patient Advocacy on RP1 + Nivolumab

As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
Blog - Melanoma360
, 
Melanoma Research
06/05/2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Data for darovasertib in combination with crizotinib presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago…
Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
Blog - Melanoma360
 | 
Melanoma Research
05/21/2026

Webinar: Post-ASCO Melanoma Research Update

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Featured image for “Webinar: Post-ASCO Melanoma Research Update”
Blog - Melanoma360
 | 
Melanoma Research
04/19/2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/10/2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
03/26/2026

Advocates Renew Call for RP1 Approval

As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
Featured image for “Advocates Renew Call for RP1 Approval”
Blog - Melanoma360
 | 
Melanoma Research
02/19/2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/05/2026

FDA Responds to Patient Advocacy on RP1 + Nivolumab

As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
Featured image for “FDA Responds to Patient Advocacy on RP1 + Nivolumab”
Blog - Melanoma360
 | 
Melanoma Research

Recent Posts

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
Jun. 05, 2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Filter by Tag